Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Kidney Neoplasms 3Carcinoma, Renal Cell 3Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thrombocythemia, Essential 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Interferon-alpha × Clear all
NCT00329368 2012-03-09

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Endocyte

Phase 1 Completed
13 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡